Abstract Library

#4636 Maximising the use of pancreatic enzyme replacement therapy (PERT) among patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) and exocrine pancreatic insufficiency (EPI)

Introduction: Patients with GEPNENs frequently develop EPI due to surgical resection or use of somatostatin analogues (SSAs), however it is significantly underdiagnosed. Untreated EPI has significant impact on overall quality of life with patients with GEPNENs.

Conference:

Presenting Author:

Authors: Grewal U, Chandar A,

Keywords: Pancreatic insufficiency, Pancreatic enzyme replacement therapy, Gastroenteropancreatic neuroendocrine neoplasm,

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4606 Neuroendocrine mess – Ectopic Cushing syndrome and severe hypokalaemia

Introduction: Cushing Syndrome (CS) is the condition resulting from hypercortisolaemia. Ectopic Cushing Syndrome (ECS) is responsible for up to 20% of all CS cases. Pancreatic neuroendocrine neoplasms (pNEN) are responsible for 10-20% of those cases.

Conference:

Presenting Author:

Authors: Corrêa Figueira C, Alves H, Bento A, Cardoso Gomes C, Oliveira A,

Keywords: Pancreatic neuroendocrine neoplasm, Hepatic neuroendocrine metastasis, Paraneoplastic syndrome, Cushing syndrome, Ectopic Cushing syndrome,

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4519 ANXA1-labelled cancer-associated fibroblasts induces tumour invasion and immunosuppressive microenvironment

Introduction: The growth pattern of a tumour is a marker for distinguishing inert from invasive tumours. In general, tumours such as the encapsulated follicular variant of papillary thyroid carcinoma show expansive growth. In contrast, invasive tumours, such as colorectal cancer and squamous cell carcinoma of the tongue, show invasive growth with infiltration into surrounding structures and have a poorer prognosis. Pancreatic neuroendocrine neoplasm (PNEN) is the heterogeneous tumour originating from peptidergic neurons and neuroendocrine cells. PNEN with a high proportion of tumour mesenchyme, especially those presenting an infiltrating stroma, have a poor prognosis. In the infiltrating mesenchyme, cancer-associated fibroblasts (CAF) play an important role. However, little research has been done on the mechanisms of how infiltrating CAF affects tumour malignancy and immune microenvironment.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Xu J, Chen J, Xu X, Ji S,

Keywords: pancreatic neuroendocrine neoplasm, tumour-associated fibroblasts, immunosuppressive microenvironment,